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Maternal immune tolerance toward the fetus is an essential requisite for pregnancy. 
While T cell functions are well documented, little is known about the participation 
of B cells. We have previously suggested that IL-10-producing B cells are involved 
in pregnancy tolerance in mice and humans. By employing murine and human 
systems, we report now that fetal trophoblasts positively regulate the generation of 
IL-10-producing B cells. We next studied the participation of hormones produced by 
the placenta as well as the fetal protein alpha-fetoprotein (AFP) in B cell modulation. 
Human chorionic gonadotropin (hCG), but not progesterone, estrogen, or a 
combination of both, was able to promote changes in B cell phenotype and boost 
their IL-10 production, which was abolished after blocking hCG. The hCG-induced 
B cell phenotype was not associated with augmented galactosylation, sialylation, 
or fucosylation of IgG subclasses in their Fc. In vitro, hCG induced the synthesis 
of asymmetrically glycosylated antibodies in their Fab region. Interestingly, AFP had 
dual effects depending on the concentration. At concentrations corresponding to 
maternal serum levels, it did not modify the phenotype or IL-10 secretion of B cells. 
At fetal concentrations, however, AFP was able to drive B cells into apoptosis, which 
may indicate a protective mechanism to avoid maternal B cells to reach the fetus. 
Our data suggest that the fetus secrete factors that promote a pregnancy-friendly 
B cell phenotype, unraveling interesting aspects of B cell function, and modulation by 
pregnancy hormones and fetal proteins.
Keywords: B cells, pregnancy, hcg, placenta, aFP, hormones, tolerance, il-10
Abbreviations: AAbs, asymmetric antibody; AFP, alpha-fetoprotein; APC, antigen-presenting cell; DC, dendritic cell; E2, 
estradiol; hCG, human chorionic gonadotropin; IL-10, interleukin 10; P4, progesterone.
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inTrODUcTiOn
B lymphocytes are a major component of the immune system 
with  pleiotropic functions, including antibody production, 
antigen-presenting capacities, and the secretion of immu-
nomodulatory cytokines. Recent experimental studies of 
autoimmunity, cancer, and infection diseases have identified 
B cells with regulatory function, supporting the notion that 
B cells participate in the maintenance of tolerance to inhibit 
or downregulate harmful immune responses. This regulatory 
function is mediated by the production of cytokines, most 
importantly IL-10, and by the ability of B cells to interact with 
other cells of the innate and adaptive immune systems (1, 2). 
Mauri and her colleagues first reported that IL-10-producing 
B cells suppress Th1 differentiation and prevent autoimmune 
arthritis development or ameliorate established disease (3). The 
regulatory effect was dependent upon the release of IL-10 because 
B cells isolated from IL-10 knockout mice as well as treatment 
with anti-IL-10 failed to prompt this protective function (4, 5). 
Carter and colleagues observed that IL-10 B cells established 
longer contact times with CD4+CD25− T  cells compared with 
IL-10 negative B cells and promoted their differentiation into 
regulatory T  cells (Treg) (6). IL-10-producing B cells can also 
suppress the maturation of dendritic cells (DCs) and influence 
their cytokine secretion (7).
The concept that IL-10-producing B cells immunomodulate 
inflammatory processes in autoimmunity brought about the 
idea that these cells may also control immunological adaptations 
during mammalian pregnancy. As the fetus is semi-allogeneic 
to its mother, the maternal immune system has to promote its 
tolerance while continuing the fight against infection. Failure 
to accommodate immune adaptations may lead to sporadic 
or recurrent pregnancy loss. We have recently reported that 
IL-10-producing B10 cells can restore pregnancy tolerance in 
a mouse model (8). Accordingly, patients with spontaneous 
abortion showed a lower proportion of so-called regulatory 
B cells when compared to normal pregnant patients at the same 
gestational age (9). In vitro, IL-10-producing B cells were able 
to inhibit the ability of T cells of producing TNF-α (9). Hence, 
IL-10-producing B cells emerge as regulators of pregnancy 
immunotolerance. The generation and regulation of these cells 
has not been explored and emerges as an important issue, yet it 
can help designing strategies to boost tolerance in patients that 
suffer from immunological pregnancy losses.
We hypothesize that hormones and other factors secreted by 
the trophoblast will be relevant in modulating B cell function. 
Pregnancy-associated hormones, such as the human chorionic 
gonadotropin (hCG), progesterone (P4), and estradiol (E2), rise 
dramatically during pregnancy and are essential for successful 
pregnancy outcome (10). Besides their biological role on prepar-
ing the endometrium for implantation [P4; (11)], promoting 
uterine blood flow and myometrial growth [E2; (12)], and 
facilitating trophoblast invasion and promoting angiogenesis 
[hCG; (12–14)], these hormones have been proposed to have 
immunomodulatory functions (15, 16). 
Alpha-fetoprotein (AFP) is produced by the yolk sac 
and fetal  liver (17). Due to its ability to cross the placenta, 
Alpha-fetoprotein (AFP) is produced by the yolk sac and fetal 
liver (17). Due to its ability to cross the placenta, AFP levels can 
be detected not only in the fetus but also within the maternal 
circulation. AFP is also a tumor marker and is secreted by sev-
eral carcinomas and has therefore immunosuppressive activi-
ties (18). It has not been explored whether AFP contributes to 
pregnancy success by modulating immune responses.
All of the above support the notion that endocrine factors 
can modify the immune response and induce fetal tolerance. 
Here, we devoted to the question whether pregnancy hormones, 
namely P4, E2, and hCG, as well as the glycoprotein AFP are able 
of affecting both IL-10 secretion, that would define the modula-
tory capacity of B cells, and antibody glycosylation patterns that 




The use of samples obtained from non-pregnant and pregnant 
mice was previously approved by the local corresponding 
authorities (Landesverwaltungsamt Sachsen-Anhalt, Referat 
Verbraucherschutz, Veterinäramt, Tötungsanzeige). Eight-week-
old IL-10eGFP (C57BL/6J background) mice were provided by 
Dr. Matthias Haury, Instituto Gulbenkian de Ciência, Lisbon 
upon MTA agreement and further bred in our facilities. Swiss 
Webster mice were purchased from Charles River (Sulzfeld, 
Germany) and maintained in our animal facility. C57/BL6 
(IL-10eGFP) transgenic females, enabling the identification of 
IL-10-producing cells by means of green fluorescent protein 
(GFP) measurement, were allogeneically mated to Swiss Webster 
males. Mice were checked twice a day for vaginal plug, whose 
presence indicated day 0 of gestation. Naïve and pregnant mice 
at day 9 of gestation were sacrificed by cervical dislocation and 
spleens removed. Day 9 of gestation was chosen to match with the 
gestation day at which SM-9 cells were generated. Splenic tissue 
was filtered through a sterile 100 μm cell strainer (BD Falcon, 
Heidelberg, Germany) and treated with erythrocyte lysis buffer. 
After lysis, single cell suspension was stained with CD19 PerCp 
(Biolegend, San Diego, CA, USA) and sorted for CD19 PerCp 
positive and GFP negative cells by FACS using an FACSAria III 
(BD, Heidelberg, Germany) while the data were analyzed by 
DIVA 8.0.1 software.
Murine B cell and Trophoblast (sM9-2) 
cocultures
The Swiss Webster mouse trophoblastic cell line SM9-2, kindly 
provided by Joan Hunt and David Wheaton (University of 
Kansas Medical Center, Kansas City, MO, USA), was cultured 
in RPMI 1640 medium containing 20% charcoaled fetal bovine 
serum (FBS), 2  mM l-glutamine, 1  mM sodium pyruvate, 
50  μM 2-mercaptoethanol, and 1% penicillin–streptomycin 
(P/S). Cells were seeded at a concentration of 5 × 104 cells/well 
on a 24-well culture dish for 24 h (Sarstedt, Newton, NC, USA). 
Trophoblast attachment to the culture dish was assessed under 
the microscope, and old medium was carefully removed. To study 
TaBle 1 | Participant characteristics.a
characteristic age (mean ± seM) smoking BMi (kg/m2) (mean ± seM) comorbidities (diabetes, hypertension, 
endocrine disorders)
Participant number
25 26.4 ± 0.56 1 (6.25%) 21 ± 0.5 0
aListed are the baseline characteristics for all female, nulliparous participants. Data are presented as means ± SEM.
TaBle 2 | Physiological hormone levels and alpha-fetoprotein levels during pregnancy.a
Treatment hcg 1st trimester P4 1st trimester e2 1st trimester aFP 1st trimester aFP 2nd trimester aFP 3rd trimester aFP fetal
Concentration 5–288,000 mIU/ml 11–90 ng/ml 188–2497 pg/ml 9–18 ng/ml 53–80 ng/ml 98–283 ng/ml 50–3000 μg/ml
aCirculating maternal hormone levels during the first trimester of pregnancy are shown for human chorionic gonadotropin (hCG), progesterone (P4), and estradiol (E2). The serum 
concentration of fetal alpha-1-fetoprotein (AFP) and maternal serum concentrations for AFP are listed for all the three trimesters of pregnancy.
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the effect of trophoblast-derived factor(s) on the generation of 
IL-10-producing B cells, 500  μl of fresh medium containing 
1 × 105 CD19+ eGFP− B cells were added to SM9-2 cells at ratio 
of 2:1 for 24 and 48 h in the presence or absence of mouse CD40 
Ligand (R&D Systems, Minneapolis, MN, USA) and CpG ODN 
M362 (InvivoGen, San Diego, CA, USA). Cell expression of 
GFP was analyzed by flow cytometry and corresponded to IL-10 
production. The 0.5–1 × 105 events were measured in each case.
Placental Tissue collection and 
Processing
Uteri of day 9 pregnant Swiss Webster mice were opened lon-
gitudinally and the fetal–placental units were separated from 
their sites of implantation. Placenta tissue was carefully prepared 
under a dissecting microscope to remove the decidua basalis and 
the tissue edges. Each placenta was dissected into four equal sized 
cubes that were further used in cocultures. The 5 × 104 CD19+ 
IL-10/GFP−-sorted B cells were added to placenta explants in 
96-well plates with 250 μl of the same media as used for SM9-2 
coculture studies. Proliferation of B cells was stimulated by the 
presence of CpG and CD40L. All cocultures were left for 24 and 
48  h. The conversion of IL-10−/GFP− cells into IL-10+/GFP+ 
B cells was analyzed by flow cytometry. The 0.5–1 × 105 events 
were measured in each case.
human samples
All experiments involving blood samples from human subjects 
were previously approved by the Ethics Committee of the Otto-
von-Guericke University (study 28/08). Non-pregnant individu-
als were fully informed about the purpose of this research and 
provided written consent prior to sampling. Participant charac-
teristics are summarized in Table 1.
B cell isolation and culture
Peripheral blood mononuclear cells (PBMCs) were isolated 
from peripheral blood of women who were not pregnant at 
the moment of blood sampling (Table  1). Using a magnetic 
separation kit (Miltenyi, Bergisch Gladbach, Germany), 
B cells were isolated from PBMCs by negative selection. B cell 
purity was above 95% (Figure S1 in Supplementary Material). 
B cells (5 × 104 cells/well) were plated in duplicates 24 h before 
treatment on 96-well plates (Sarstedt, Newton, NC, USA) with 
150  μl RPMI 1640 medium supplemented with 3% FBS and 
1% P/S. Afterward, cells were either used without stimulation 
(for hCG treatment and treatment with JEG-3 supernatant) 
or stimulated with the combination of CD40L (1 μg/ml) and 
CpG (10 μg/ml) and treated either with physiological concen-
trations of recombinant hCG (100  mIU/ml, Ovitrelle, Merck 
Serono, Darmstadt, Germany), P4 (30  ng/ml, Sigma-Aldrich, 
Taufkirchen, Germany), E2 (1000  pg/ml, Sigma-Aldrich, 
Taufkirchen, Germany), a combination of P4 and E2, AFP 
(Abnova, Walnut, CA, USA) at a concentration found in 
maternal serum (first trimester: 0.015 μg/ml, second trimester: 
0.06 μg/ml, and third trimester: 0.2 μg/ml), or AFP at a concen-
tration found in fetal serum (50 μg/ml) for 24 h. Concentrations 
used were chosen as they represent physiological values during 
pregnancy, summarized in Table 2. Medium only was used as 
control. For all experiments cells were maintained at 37°C and 
5% CO2. A scheme illustrates the culture conditions designed 
for our paper (Figure S2 in Supplementary Material).
cell staining and Flow cytometry
Harvested human cells were stained for the extracellular markers 
CD19 (FITC), CD27 (PerCp), and CD24 (AF647) (Biolegend, 
San Diego, CA, USA). Following O/N fixation, permeabilization 
(eBioscience, San Diego, CA, USA), and intracellular IL-10 
(PE) (Biolegend, San Diego, CA, USA) staining, cells were 
analyzed by flow cytometry. A total of 1  ×  104 events were 
measured in each case. CD27+ and CD24high cells were gated, 
and within this population, the coexpression of CD19 and IL-10 
was recorded. Samples were measured using a FACS Calibur 
(BD, Heidelberg, Germany), while the data were analyzed by 
BD CellQuest Pro software.
cytokine and immunoglobulin  
enzyme-linked immunosorbent assay
Supernatants from B cells were collected after 24 h (cytokines) 
or 12  days (immunoglobulin; Ig) (Figure S2 in Supplementary 
Material). IL-10 cytokine secretion was determined using a human 
IL-10 OptEIA™ Enzyme-Linked Immunosorbent Assay (ELISA) 
kit (BD Biosciences, Heidelberg, Germany). Human IgM, IgA, 
and IgG levels were quantified using Ig ELISA kits from Bethyl 
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Laboratories (Montgomery, TX, USA). All steps were performed 
according to the technical data sheet/manufacturer’s protocol. 
Cytokine and Ig levels for duplicate samples were quantified and 
analyzed using a BioTek Synergy HT Multi-Mode Microplate 
Reader with Gen5 software.
apoptosis/cell Viability assay
Harvested B cells were washed with cold PBS and stained 
with FITC Annexin V and propidium iodid as indicated by 
manufacturer’s instructions (BD Pharmingen™ FITC Annexin 
V Apoptosis Detection Kit I, Heidelberg Germany). Data were 
analyzed by flow cytometry within 1 h.
caspase activity assay
We measured caspase-3 and -7 activities using a Caspase-Glo 
3/7® assay (G8091, Promega, Madison, WI, USA) following 
treatment of B cells with AFP. Cell culture plates containing cells 
were harvested and set aside to equilibrate to RT for 30 min. The 
100 μl of Caspase-Glo®3/7 reagent had been added to each well, 
the contents of wells were gently mixed using a plate shaker at 
300–500 rpm for 30 s. Following incubation at RT for 1 and 3 h, 
the luminescence was measured using a BioTek Synergy HT 
Multi-Mode Microplate Reader according to the manufacturer’s 
instructions.
human B cell and Trophoblast (Jeg-3) 
cocultures
The hCG-producing human choriocarcinoma trophoblast cell 
line (JEG-3) purchased from Cell Line Service (CLS, Eppelheim, 
Germany) was cultured in RPMI 1640 medium supplemented 
with 10% FBS and 1% P/S. Cells were trypsinized and seeded 
at a concentration of 5 × 104 cells/well on a 24-well culture dish 
for 24  h (Sarstedt, Nümbrecht, Germany). Human B cells also 
incubated for 24 h were harvested, suspended in fresh charcoaled 
medium, and cocultured (1:1) with JEG-3 cells in the presence or 
absence of 1 μg/ml CD40L and 10 μg/ml CpG for further 24 h. 
To study the influence of hCG on the expansion of pregnancy 
protective IL-10-producing B cells, an anti-hCG antibody (Santa 
Cruz, San Francisco, CA, USA), blocking hCG from binding to 
its target receptor, was added to cell cultures. Cells were stained 
for CD19, CD24, CD27, and IL-10 as indicated previously and 
analyzed by flow cytometry. Supernatants were collected for 
analysis of IL-10 by ELISA.
igg glycosylation analysis
The glycosylation of the IgGs from the culture were analyzed 
as described previously with minor modifications (19). Briefly, 
human IgGs were affinity captured from the culture medium 
using CaptureSelect IgG-Fc (Hu) beads (Invitrogen, Bleiswijk, 
The Netherlands). After elution with 100 mM formic acid (Fluka, 
Steinheim, Germany), samples were dried by vacuum centrifu-
gation. The purified antibodies were sequentially reconstituted 
in 20 μl 50 mM ammonium bicarbonate buffer (pH 8.0; Sigma-
Aldrich, Taufkirchen, Germany) in 15% acetonitrile (Biosolve 
BV, Valkenswaard, The Netherlands). After 5 min of incubation 
on a multiwell plate shaker, 20 μl ultrapure water containing 
330 ng sequencing grade modified trypsin (Promega, Madison, 
WI, USA) was added, followed by a further 5 min of incubation 
on a shaker and O/N incubation at 37°C. The resulting tryptic 
digest was subjected to subclass specific glycopeptides analysis 
by LC-MS. Analysis was performed with nanoLC-reversed 
phase (RP)-electrospray (ESI)-ion trap (IT)-MS(/MS) on an 
Ultimate 3000 RSLCnano system (Thermo Scientific, Dreieich, 
Germany) coupled with an amaZon speed ESI-IT-MS (Bruker 
Daltonics, Bremen, Germany). A precolumn (Acclaim PepMap 
100 column, 100  μm ×  20  mm, particle size 5  μm, Thermo 
Scientific) was used to wash and concentrate the sample, and 
separation was achieved on an Acclaim PepMap RSLC C18 
nanocolumn (75 μm ×  150  mm, particle size 2 μm, Thermo 
Scientific, Dreieich, Germany) with a flow rate of 700 nl/min. 
The following linear gradient was used, with solvent A consisting 
of 0.1% formic acid in water and solvent B of 95% acetonitrile, 
5% water: t = 0 min, 3% solvent B; t = 5 min, 1% B; t = 20 min, 
27% B; t = 21 min, 70% B; t = 23 min, 70% B; t = 24 min, 3% 
B; and t = 43 min, 3% B. The sample was ionized in positive ion 
mode with a Captive sprayer (1200 V) with a tapered tip (20 μm 
ID). The solvent was evaporated at 180°C with a nitrogen flow of 
3 l/min. A nanoBooster (Bruker Daltonics) was mounted onto 
the source and saturated the nitrogen flow with ACN to enhance 
the sensitivity (0.2 bar). The MS1 ion detection window was set 
at 550–1800  m/z. IgG Fc-glycopeptides were identified based 
on their retention times and the monoisotopic masses of the 
protonated species. Internal calibration of LC-MS spectra was 
performed in Bruker Data Analysis 4.0 using a list of known 
glycopeptides, before exportation of the data to the mzXML 
format, extraction, and exploration in Microsoft Excel.
hybridoma cell culture
Anti-DNP MAb-secreting hybridomas were prepared and 
characterized as originally described by Köhler and Milstein and 
mentioned in the study by Margni and colleagues (20). Fusion 
partners were spleen cells from BALB/c mice immunized with 
dinitrophenylated human gamma globulin (DNP-HGG) and the 
NSO myeloma cell line. A hybridoma secreting symmetrically 
and asymmetrically glycosylated anti-DNP antibodies of the 
IgG1 subclass was selected (21). Cells were suspended in RPMI 
1640 medium (supplemented with 10% FBS and NaHCO3 2 g/l, 
20 U/ml penicillin, and 20 mg/ml streptomycin) at 5 × 105 cells/
ml and incubated in the presence or absence of recombinant hCG 
(50  mIU/ml, Ovitrelle). Cultures were performed as triplicates 
in 96-well flat-bottom plates (Corning Inc., Corning, NY, USA). 
After 24 or 48 h of incubation, the cell culture supernatants were 
harvested and processed as described below.
assessment of asymmetric Fab 
glycosylation of anti-DnP antibody 
by con a-Binding assay
The property of the carbohydrate prosthetic group present in 
the Fab region of asymmetrically glycosylated IgG molecules 
to bind steadily to Concanavalin A (Con A) was applied tak-
ing into account that this lectin binds molecules containing 
α-d-mannopiranosyl, α-d-glucopiranosyl, and sterically related 
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residues (22). Samples were diluted 1:10 in Con A buffer (0.025 M 
Tris–HCl, 0.2 M NaCl, and 0.003 M each of CaCl2, MgCl2, and 
MnCl2; 0.02% Na3N; pH 7.2), mixed with appropriate volume of 
either Con A buffer, or Con A-Sepharose suspension (Sigma, 1 ml 
of 50% gel suspension/mg of protein) and kept for 2 h at 4°C with 
occasional agitation. After supernatant collection, total as well 
as unbound anti-DNP IgG was measured by ELISA as described 
previously (23). The percentage of asymmetrically glycosylated 
IgG1 monoclonal antibody (mAb) in the hybridoma culture 
supernatants was calculated from the statistical linear regression 
analysis of both ELISA line draws.
statistical analysis
Data were examined for normality using the Kolmogorov–
Smirnov test; results are expressed as the means or means ± SEM. 
Differences within the groups were compared using repeated 
measures one-way ANOVA. Where multiple comparisons were 
made, Bonferroni adjustment was applied/Bonferroni multiple 
post t test were applied to evaluate the differences of means of 
multiple groups. Statistical testing was carried out using Prism 5 
software (GraphPad Software, 2007 edition, La Jolla, CA, USA). 
A confidence interval of 95% or a p-value of <0.05 was consid-
ered significant and indicated as *, p < 0.01 indicated as **, and 
p < 0.001 indicated as ***.
resUlTs
Trophoblasts Themselves or Trophoblast-
Derived Factors Promoted the generation 
of Murine il-10-Producing B cells In Vitro
As IL-10-producing B cells were recently proposed to be 
important regulators of feto-maternal tolerance and knowing 
that the  fetus itself, and most specifically, the trophoblast, 
secretes modulating factors, we first studied whether tropho-
blasts were able to influence B cell phenotype and intracellular 
IL-10 production in a mouse model. For this, we isolated 
splenic CD19+GFP− B cells from transgenic modified C57BL/6 
(IL-10eGFP) mice whose IL-10 secreting cells can be visualized 
as they express GFP. We employed either virgin mice or pregnant 
mice (day 9 of pregnancy). Unstimulated B cells as well as CpG/
CD40L-stimulated B cells were cocultured with the murine 
trophoblast cell line SM9-2 at a ratio of 2:1 for 24 and 48 h. This 
cell line was originally generated from placentas of pregnant 
mice at day 9 of gestation. The conversion of IL-10− cells into 
IL-10+ cells was analyzed and quantified by flow cytometric 
detection of GFP. We observed a relevant conversion of IL-10− 
B  cells  into IL-10+ B cells after coculture of trophoblasts with 
B cells (Figure 1A). The generation of IL-10-producing B cells 
from total cells was observed in both B cells obtained from virgin 
or pregnant cell donors (Figure 1A). This confirms the impor-
tant role of trophoblast cells and or their factors in converting 
B cells into B cells with the ability of produce IL-10.
In order to replicate a more physiological setting, the second 
experimental design utilized placental tissue derived from 
pregnant Swiss Webster mice on day 9 instead of a trophoblast 
cell line. Placenta explants were obtained from pregnant day 9 
Swiss Webster mice. CD19+GFP− B cells were collected from 
virgin or 9 day pregnant C57BL/6 (IL-10eGFP) mice previously 
mated with Swiss Webster male and incubated with placenta 
explants for 24 or 48 h. As shown in Figure 1B, the presence of 
placenta explants induced the differentiation of IL-10 negative 
B cells into B cells able to secrete IL-10. This effect was observed 
independently of whether the cell donors were pregnant or not 
(Figure 1B). Hence, fetal trophoblasts generate factors that are 
able to promote the de novo generation of IL-10-producing 
B cells that are important for fetal tolerance.
Trophoblast and Trophoblast-Derived 
soluble Factors Promoted the 
generation of human il-10-Producing 
B cells In Vitro; This effect Was 
abrogated by Blocking hcg
To understand whether the phenomenon observed in a murine 
system is relevant for human pregnancies, we next we cocultured 
stimulated total B cells with human choriocarcinoma tropho-
blastic cells (JEG-3) for 24 h. Upon flow cytometry evaluation, 
we observed a statistically significant increase in the number 
of CD19+CD24hiCD27+IL-10+ cells (Figure 2) and active secre-
tion of IL-10 into the supernatant (Figure S3 in Supplementary 
Material). JEG-3 supernatant was also able to induce IL-10 
secretion by isolated CD19+ cells (Figure S4 in Supplementary 
Material), which suggests a soluble factor as responsible for 
this. As we recently showed that hCG secreted by JEG-3 has an 
important effect in the number and functionality of T cells (15), 
we next aimed to investigate whether hCG was the mediator of 
the effect in B cell phenotype. For this, we blocked hCG using 
an anti-hCG antibody, which indeed abrogated JEG-3-induced 
increase of IL-10-producing B cells within total B cells (Figure 2). 
Thus, trophoblast-derived hCG is able to change the phenotype of 
B cells and turn them pregnancy protective.
hcg, but not P4 or e2, could induce a 
B cell Phenotype change and an increase 
in the number of il-10-Producing B cells
To unequivocally confirm the participation of hCG in the induc-
tion of a pregnancy protective phenotype, we stimulated total 
B cells with CD40L (5 μg/ml) and CpG (10 μg/ml), which were 
further cocultured in vitro with recombinant hCG. To evaluate 
whether other pregnancy-relevant hormones are also able to 
influence the phenotype of B cells, we repeated the experiments 
and incubated total B cells with P4, E2, or a combination of 
the latter for 24  h. We observed a significant increase in the 
CD19+CD24highCD27+IL-10+ cell population when adding 
recombinant hCG compared with cells cultured without hor-
mones (Figure  3A). Interestingly, and as we reported before 
(9), it seems that hCG has an additive effect to CD40L/CpG as 
treatment with both boosts IL-10 production in a magnitude 
that is higher than the addition of any of them alone (Figure 
S4 in Supplementary Material). The addition of P4, E2 had no 
statistically relevant effect in generating this cell population out 
of total B cells (Figure 3B). Thus, similarly as trophoblasts or 
FigUre 1 | Trophoblasts themselves or trophoblast-derived factors promoted the generation of murine il-10-producing B cells in vitro. (a) Naive 
and pregnant (day 9) female IL-10eGFP (C57BL/6 background) mice were sacrificed and total CD19+ GFP− B cells isolated. CD40L/CpG-stimulated B cells as 
well as unstimulated controls were cocultured for 24 h with murine trophoblast cells (SM9-2). The generation of IL-10-producing B cells was calculated by 
evaluating IL-10 expression in total B cells using flow cytometry. After coculture of B cells with trophoblast cells, a significant conversion of IL-10− into IL-10+ 
B cells compared to stimulated cells cultured alone was observed. Overall, the number of IL-10+ B cells increased with incubation time. Comparing the frequency 
of generated IL-10+ B cells within both groups demonstrated no statistical significance, whether CD19+eGFP− B cells were obtained from naïve or pregnant mice 
following 24 and 48 h culture. (B) Here, isolated CD19+ GFP− B cells were cocultured with placenta explants from pregnant day 9 Swiss Webster mice for 24 and 
48 h. The generation of IL-10-producing B cells was calculated by evaluating IL-10 expression in total B cells using flow cytometry. The 24 h coculture of 
CD19+eGFP− B cells with placenta explants demonstrated a significant conversion into IL-10+ B cells. This effect was observed, whether B cells has been 
stimulated or not and the overall number of IL-10+ B cells increased with incubation time. Comparing the frequency of generated IL-10+ B cells within each group 
demonstrated no statistical significance, whether CD19+GFP− B cells were obtained from naïve or pregnant mice following 24 and 48 h culture (B). Data are 
presented as means + SEM. Statistical analysis was carried out by repeated measures two-way ANOVA followed by Bonferroni correction for multiple analysis 
(*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001).
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trophoblast supernatant, recombinant hCG, but not P4 and E2, 
are able to generate B cells that express extracellular markers 
previously related to so-called regulatory B cells. Additionally, 
these cells actively secrete IL-10 as we could observe using flow 
cytometry (Figure S5 in Supplementary Material).
neither hcg nor Other Pregnancy 
hormones Were able to affect the 
concentration of igs
We next aimed to understand whether the effect of hCG was 
exclusively related to IL-10-producing B cells involved in cellular 
immunology or whether hCG was able to influence the Ig produc-
tion by B cells cultured for 12 days, so that they produce antibodies. 
As tested in vitro, the addition of exogenous pregnancy hormones 
and AFP had no impact on Igs, as we found no differences in the 
levels of human IgM, IgA, and IgG in supernatants from isolated 
B cells cultured for 12 days with or without the addition of hCG, 
P4, E2, P4 plus E2, or AFP at different concentrations (Figure S6 
in Supplementary Material).
The Fc glycosylation Profile of igg 
subclasses Was Unaffected by Pregnancy 
hormones and aFP
After observing that hCG, but none of the other tested hormones, 
was able to influence the phenotype of B cells albeit not their 
ability to secrete cytokines, we next intended to clarify whether 
hCG is able to influence the glycosylation profile of IgG, thereby 
affecting the quality of the immune response. For this, we isolated 
FigUre 2 | Trophoblasts or trophoblast-derived factors promoted the 
generation of human il-10-producing B cells in vitro: this effect could 
be abrogated by blocking hcg. CD19+ isolated B cells from PBMCs 
obtained from non-pregnant female donors were cultured in the presence of 
JEG-3 trophoblast cells. A significant increase in the proportion of 
CD19+CD24hiCD27+IL-10+ cells was registered by flow cytometry. The 
blockage of hCG by using an anti-hCG antibody abrogated this effect. Each 
square represents one single subject. Data are presented as single values/
donor and means. Statistical analysis was carried out by repeated measures 
one-way ANOVA followed by Bonferroni correction for multiple analysis 
(*p ≤ 0.05 and **p ≤ 0.01).
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human serum IgG in order to assess the subclass-specific glyco-
sylation profiles and potential differences based on the addition of 
pregnancy hormones. The glycosylation profile of the Fc peptides 
featured galactosylation, sialylation, and fucosylation for IgG1 
and for IgG2 and IgG3 combined. The analysis revealed no dif-
ferences in the N-glycosylation after treatment with recombinant 
pregnancy hormones or different AFP concentrations and subse-
quent 12-day culture (Figures S7A,B in Supplementary Material; 
glycosylation profiles for combined IgG2/3 are not shown). This 
indicates that Fc glycosylation processes are not affected by preg-
nancy hormones and AFP in vitro.
hcg increased Fab asymmetric 
glycosylation of hybridoma 112D5 cells
To determine a potential effect of hCG on the synthesis of 
pregnancy protective AAbs, we sampled supernatant from 
hybridoma 112D5 cells following culture for 24 and 48 h with 
recombinant hCG at the same concentrations that were effective 
in influencing B cell phenotype or standard serum as controls. 
We were able to show that the addition of recombinant hCG 
provoked an enhancement in the percentage of IgG1 anti-DNP 
antibodies synthesized 112D5 by hybridoma cells that were able 
to steadily bound to Con A following 24 h culture (Figure 4). 
These results confirm the ability of hCG to induce the synthesis 
of AAbs, namely IgG antibodies asymmetrically glycosylated in 
their F(ab).
aFP at Maternal concentrations had no 
effect on B cell Phenotype or il-10 
Production, but Fetal concentrations of 
aFP Drove B cells into apoptosis
To understand whether AFP, which is relevant during embryonic 
life, is also important for B cell function, we tested whether AFP 
influences B cell phenotype and IL-10 production. For this, we 
added recombinant AFP in concentrations corresponding to the 
physiological values observed in serum for the three trimesters 
as well as to the fetal concentrations to total B lymphocytes from 
peripheral blood of non-pregnant women. In vitro stimulation 
of total B cells with AFP at maternal or fetal concentrations had 
no significant effect on the cellular phenotype of B cells or their 
IL-10 secretion (Figures 5A,B). However, when examining the 
dot plots, we observed a shift in the cell population induced by the 
fetal concentration of AFP that suggested cell death (Figure 5C). 
To deeper investigate this interesting observation, B cells were 
treated with fetal concentrations of AFP and after 24 h, stained 
with an Annexin V and PI. As shown in Figure 6, treatment with 
50 μg/ml AFP-induced apoptosis (Figures 6A,B) and cell death 
(Figure 6C) of cultured total B cells to a great extent, whereas 
significantly more viable cells remained following culture in 
standard medium alone or with the addition of CD40L/CpG 
(Figure  6A). To assess whether caspase activity is influenced 
by AFP, we employed a Caspase-Glo® 3/7 luminescent assay. 
As shown in Figure 6D, AFP at fetal concentrations augmented 
caspase-3 and -7 activity of B cells, while supplementation with 
CpG and CD40L inhibited these enzymes as anticipated (see 
also Figure S8 in Supplementary Material). Hence, AFP has no 
effect on B cells when tested at maternal concentrations. Used at 
fetal concentrations, however, it drives B cells into apoptosis. We 
speculate that this mechanism may provide a protective barrier 
for maternal B cells that try to reach the fetus.
DiscUssiOn
The quality of the maternal immune response during pregnancy 
dictates its outcome. Important players are cells of the innate 
and adaptive immune system and the cytokines they produce. 
B cells and in particular B cells with the ability to produce IL-10 
emerge as novel mediators of pregnancy tolerance (24, 25) and 
understanding the pathways that lead to their generation is vital 
to evaluate their possible therapeutic application.
Here, we hypothesized that molecules produced by the fetal 
trophoblast are able to regulate the phenotype of B cells and their 
ability to produce the immunomodulatory molecule IL-10. We 
focused our attention particularly on pregnancy hormones as 
B cells express the respective hormone receptors. Very interest-
ingly, our results confirm that from all hormones, hCG is the 
only one able to convert CD19+ cells into IL-10-producing B cells 
and to also affect the capability of plasma cells in secreting AAbs. 
Since from all tested hormones, hCG is unique in its property 
to be exclusively secreted by the placenta during pregnancy, our 
data confirm the active participation of the fetus in establishing 
and maintaining its own tolerance. B cells are not only pregnancy 
protective but can also synthesize antibodies that, if reaching the 
fetus, can danger pregnancy outcome or fetal health (26,  27). 
We  found that fetal concentrations of AFP drive B cells into 
apoptosis. This suggests the existence of fetal mechanisms that 
regulate the entrance of putatively dangerous B cells and so avoid 
their negative effects. Overall, our data show that the fetus is able 
to modulate the maternal immune response to its own benefit.
We first undertook studies using a murine system. In  par-
ticular, we took advantage of a mouse strain that allowed us 
FigUre 4 | The addition of hcg augmented the proportion of aabs.  
A hybridoma secreting symmetrically and asymmetrically glycosylated anti- 
DNP antibodies of the IgG1 subclass was selected for this experiment. Cells 
were incubated in the presence or absence of recombinant hCG (Ovitrelle, 
50 mIU/ml). After 24 and 48 h of incubation, the supernatants were harvested 
and processed. Percentages of total and symmetric IgG1 monoclonal 
antibodies in the hybridoma culture supernatants were assessed by Con 
A-binding assay followed by ELISA. The proportion of AAbs was calculated 
based on the difference between total and symmetric antibodies and 
depicted as percentage. Results are shown as single values with means from 
three experiments. Statistical analysis was carried out by two-way ANOVA 
followed by Bonferroni corrections for multiple comparisons (*p ≤ 0.05).
FigUre 3 | hcg induced a B cell phenotype change and an increase in the number of il-10-producing B cells. (a) Following magnetic isolation of 
untouched CD19+ B cells from human PBMCs, B-lymphocytes were cultured for 24 h in charcoaled medium (control) or charcoaled medium with stimulation 
(CD40L/CpG) in the presence of recombinant hCG (100 mIU/ml), P4 (30 ng/ml), E2 (1000 pg/ml), or the combination of P4 and E2. Extracellular B cell markers as 
well as intracellular IL-10 production were evaluated by flow cytometry. In vitro application of recombinant hCG (100 mIU/ml) to total B cells provoked a significant 
increase in the CD19+CD24hiCD27+IL-10+ cell population. (B) Incubation of B cells with P4, E2, or a combination of both did not alter their phenotype. Each square 
represents one single subject and means are showed. Statistical analysis was carried out by repeated measures one-way ANOVA followed by Bonferroni correction 
for multiple analysis (*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001).
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to negatively select and exclude GFP+/IL-10+ B cells. If the 
cultured non-producing IL-10 cells began secreting it, their 
detection was possible by measuring GFP in the system. This 
way we could prove a significant conversion of IL-10 nega-
tive into IL-10-producing B cells after in  vitro coculture with 
an allogeneic trophoblast cell line. The same result could be 
obtained when using semi-allogeneic placenta explants. Hence, 
trophoblast-secreted factors can stimulate the IL-10 production 
by B cells. The anti-inflammatory cytokine IL-10 has a wide 
range of functions. Principally, it inhibits the production of pro-
inflammatory cytokines, thus shifting the seesaw toward a Th2 
response by inhibiting the production of Th1 cytokines. In the 
1980s and 1990s, much attention was paid to the cytokine ratio 
and a central role for Th2 vs. Th2 cytokine was proposed for 
pregnancy to be successful (28). With the first papers reporting 
dispensability of Th2 cytokines for murine pregnancy (29) this 
concept changed and the attention was rather focused on cel-
lular mechanisms leading to active tolerance to the fetal antigens 
(30, 31) rather than cytokine balance. Nevertheless, even though 
the absence of IL-10 itself does not jeopardize tolerance estab-
lishment (29), IL-10 seems to be relevant to reverse the harm-
ful effect of lipopolysaccharide (LPS)-driven pregnancy loss 
(32, 33). In IL-10-deficient mice, the pro-inflammatory cytokine 
FigUre 5 | aFP at maternal or fetal concentrations did not affect the proportion of cD19+cD24hicD27+il-10+ cells within B cells, while aFP at fetal 
concentrations caused a positional shift within the total B cell population. (a) CD19+CD24hiCD27+IL-10+ cell numbers within isolated B cells remained 
unchanged following application of AFP at maternal or fetal serum concentration. (B) The addition of AFP had no impact on the IL-10 secretion investigated in the 
culture supernatants by ELISA. (c) We did observe a change in the actual dot plot analysis following addition of fetal serum AFP levels. CD24hi and CD27+ cells 
were identified on an FSc vs. SSc dot plot using free-drawn regions. The population could be easily identified following application of standard medium, CD40L/
CpG-stimulated medium, and the combination of CD40L/CpG and maternal serum AFP level during first trimester. However, it was not possible to identify this 
double-positive population following the addition of fetal serum AFP levels. Data are either presented as means plus SEM (a,B) or FSc vs. SSc dot plot using a 
free-drawn region. Statistical analysis was carried out by repeated measures one-way ANOVA followed by Bonferroni correction for multiple analysis. Flow cytometry 
data were analyzed using BD CellQuest Pro software.
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TNF-α is mediating the adverse effects of LPS in pregnancy (34). 
Additionally, fetuses born from IL-10-deficient mothers were 
growth restricted (32), so that it can be concluded that while 
IL-10 may not be essential to pregnancy to come to end, it is 
needed for proper fetal growth and to protect from infections.
Using cells from non-pregnant female donors, we could 
confirm that trophoblast-secreted factors were able to aug-
ment the proportion of so-called regulatory B cells, namely, 
IL-10-producing CD19+CD24hiCD27+ cells. We next sought to 
understand which trophoblast-secreted mediators are involved in 
the stimulation of IL-10 production by B cells. Having recently 
reported that the hormone hCG, produced by trophoblasts, is 
able to promote the conversion of Foxp3− into Foxp3+ cells, thus 
contributing to tolerance (15), we asked whether hCG is able 
to support IL-10 production by B cells. Indeed, hCG blockage 
hampered the positive effect of trophoblasts on IL-10 production. 
FigUre 6 | aFP added at fetal concentration induced apoptosis and necrosis in total B cells. (a–c) 5 × 104 isolated B cells were stimulated by CD40L/
CpG (gray bars), stimulated and exposed to 50 μg/ml AFP (black bars), or incubated in standard medium as a control (white bars) for 24 h. The percentage of 
viable, apoptotic, and necrotic cells in the total B cell population was assessed using the FITC Annexin V Apoptosis Detection kit with flow cytometric analysis. 
Assessment of B cell membrane asymmetry following AFP application demonstrated a significant decrease in the percentage of viable cells and a significant 
increase in the percentage of apoptotic and necrotic cells compared to the application of stimulated medium. (D) Measurements of caspase activity using the 
Caspase-Glo® 3/7 assay showed a significant increase in caspase-3 and -7 activities following AFP treatment compared with CpG/CD40L treatment only. Results 
are expressed as a percentage or Luminescence RLU and presented as means ± SEM. Statistical analysis was carried out by repeated measures one-way ANOVA 
followed by Bonferroni correction for multiple analysis (*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001).
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The addition of recombinant hCG had the same effect as first 
trimester trophoblast supernatant and could boost the produc-
tion of IL-10 by CD19+CD24hiCD27+ cells. Thus, hCG has an 
important role in switching B cells to a phenotype that supports 
pregnancy. Interestingly, other pregnancy hormones that are 
produced, albeit not exclusively, by the placenta (e.g., P4 and E2) 
had no effect on B cell phenotype, remarking the unique proper-
ties of hCG. Interestingly, hCG has been reported to have other 
immunomodulatory functions: it can modulate the phenotype of 
macrophages and DCs is able to induce uNK cell proliferation, 
suppress Th1 cytokine production by T cells and generate Treg 
out of naïve T cells [revised in Ref. (16)].
B lymphocytes are best known for their capability to secrete 
Ig, which enables them to identify and neutralize foreign 
antigens. Despite of an overall four-chain structure, antibodies 
differ considerably in their glycosylation sites, both in number 
and location (macroheterogeneity) and in glycan structures 
(microheterogeneity). Such variations within the conserved 
glycosylation site on IgG, for example, modulate its biological 
activity resulting in different effector functions. During normal 
pregnancy, IgG glycosylation changes showing an increase of 
galactosylation and sialylation and an accompanying decrease in 
the percentage of bisecting GlcNAc (19, 35, 36). Structural changes 
in glycosylation are one mechanism to favor pregnancy success 
by reducing alloreactive immune responses (20). Previous studies 
demonstrated that asymmetrically glycosylated IgG antibodies 
(AAbs) are IgG molecules with their Fab portion(s) containing a 
glycan chain; they are increased in maternal serum and placental 
tissue during normal human pregnancy, particularly in response 
to Th2 interleukins, namely IL-4, IL-6, and IL-10 (21). Moreover, 
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hormonal influences and specifically P4 have been shown to 
provoke their release (22). This seems to be relevant for preg-
nancy outcome as women with recurrent spontaneous abortion 
presented lower asymmetric antibody (AAbs) levels than women 
undergoing normal pregnancies (23). These antibodies are likely 
to block immune responses, including complement fixation and 
phagocytosis, thus protecting the fetus from a potential immune 
attack by the mother.
We next studied the effect of hCG on antibody quantity and 
quality. Neither hCG nor the other tested hormones induced a 
change in the concentration of Igs produced after 12-day culture. 
Recently, much attention has been put on differentially glyco-
sylated antibodies (24, 37, 38). While no changes in galacosyla-
tion, bisection, fucosylation, or sialyation of the Fc region could 
be observed after in  vitro treatment of B cells with pregnancy 
hormones, we provide evidences that, at least in  vitro, hCG 
increased the production of asymmetrically glycosylated IgG 
antibodies (AAbs). So-called AAbs are IgG molecules with their 
Fab portion(s) containing a glycan chain. These antibodies have 
been described some time ago and were described to be preg-
nancy protective (20). Indeed, they are not only present in the 
placenta from normal pregnant women (39) but also increased in 
the maternal serum during pregnancy compared to non-pregnant 
individuals (23). These antibodies have been postulated to bind 
detrimental antibodies in order to block immune responses, 
including complement fixation and phagocytosis, thus protect-
ing the fetus from a potential immune attack by the mother. 
Patients with recurrent spontaneous abortion had low levels of 
these AAbs. It has been postulated that P4 is able to induce the 
asymmetric glycosylation (22). Gutiérrez and colleagues identi-
fied IL-6 as an important factor modulating AAbs (40), and it 
is known that trophoblast-derived IL-6 interacts with IL-6-R on 
the trophoblasts, resulting in hCG release (41). This is for sure 
a quite interesting pathway to study in the future. In contrast to 
the favorable effect proposed for AAbs on pregnancy outcome, 
so-called natural antibodies are suggested to provoke autoreactiv-
ity due to their polyreactive nature (42). Natural antibodies are 
produced by a subset of B cells called B1a B cells, whose number 
is significantly reduced during third trimester of healthy pregnant 
women, as our laboratory has shown (43). The B1a B cell count, 
however, remained elevated in preeclamptic patients and produce 
autoantibodies against angiotensin II type 1 receptor responsible 
for disease manifestation (43). Abnormally increased levels of 
hCG may be responsible for the autoantibody production (43). 
Thus, hCG emerges as a hormone with a relevant role in B cell 
regulation: at levels compatible with normal pregnancies, it sup-
ports the function of B cells that contribute to tolerance, while 
at levels observed in pathologic pregnancies, it can stimulate B1 
a B cells to produce antibodies that are pregnancy deleterious 
[revised in Ref. (25)]. In this context, it is for sure interesting to 
study how pregnancy friendly vs. pregnancy dangering cytokines 
work together with hormones to modulate B cells.
Alpha-fetoprotein is an immunomodulatory glycoprotein, 
mainly produced by the fetal liver and able to diffuse across the 
placental barrier into the maternal blood circulation. A series of 
studies have proposed that AFP is able to regulate other immune 
cells. Tumor-derived AFP causes suppression of T lymphocyte 
responses (44). Here, we intended to understand the effect of 
fetus-derived AFP on B cells, in particular, how AFP impacts 
on their capacity to produce IL-10. We found that concentra-
tions comparable to the levels observed in maternal serum 
during pregnancy had no effect on B cell phenotype and IL-10 
production. However, when used at concentrations observed at 
the fetal side, AFP significantly induced total B cell apoptosis 
and death. Further experiments assessing the caspase activity 
supported this notion and demonstrated that the activity of cas-
pase-3 and -7 was enhanced when total B cells were treated with 
elevated  levels of AFP. Um and colleagues who illustrated some 
time ago that AFP induces apoptosis in antigen-presenting cells 
(APCs), particularly DCs. AFP-treated DCs also produced lower 
levels of IL-12 and TNF-α, thereby downscaling a Th1 response 
(18). The mechanisms underlying AFP-induced apoptosis are yet 
not known but it is known that at least in DCs leads them to 
become dysfunctional and change their cytokine secretion profile 
(18). Our data strongly suggest that AFP at concentrations present 
in fetal compartments drives B cells to death. This may constitute 
one unexplored mechanism of fetal protection. By driving B cells 
into apoptosis, AFP hinders them to reach fetal compartments 
where they could either act as APCs or initiate the production of 
detrimental Igs.
In conclusion, we have showed that a particular soluble factor 
produced by the placenta, namely hCG, is essential to modulate 
the phenotype of B cells and their ability to produce IL-10. 
Furthermore, hCG promotes the generation of pregnancy protec-
tive AAbs. Thus, the fetus governs its own tolerance by secreting 
hCG. AFP is able to drive B cell into apoptosis if used at fetal 
concentrations. This may also represent a protection mechanism 
induced by the fetus. Overall, our data impressively show how 
substances produced by the fetus itself are active participants of 
its own survival. Our findings contribute to the understanding of 
the fascinating phenomenon of pregnancy tolerance.
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